Preclinical studies provide a rationale for examining a role for sunitinib in the treatment of breast cancer. However, in this large, multicenter trial, the combination of sunitinib with docetaxel did not prolong progression-free or overall survival when compared to docetaxel alone, and it appeared to be less well tolerated. The role for sunitinib remains to be established for the treatment of breast cancer.
Preclinical studies provide a rationale for examining a role for sunitinib in the treatment of breast cancer. However, in this large, multicenter trial, the combination of sunitinib with docetaxel did not prolong progression-free or overall survival when compared to docetaxel alone, and it appeared to be less well tolerated. The role for sunitinib remains to be established for the treatment of breast cancer.
Sunitinib Disappoints in First-line Phase 3 Trial in Advanced Breast Cancer
October 1, 2012